Replidyne restructures, seeks alternatives

RDYN restructured and reduced headcount to 54 from 81. The company also said it will seek strategic alternatives, including making an acquisition, merging or being acquired.

RDYN will continue its ongoing placebo-controlled Phase III trial of faropenem for acute exacerbation of chronic bronchitis (AECB), for which results are expected next year. The company reiterated that it will not conduct trials of the oral penem antibiotic in acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP) without a partner. In 2006, FDA declined to approve faropenem for ABS and AECB based on non-inferiority trials. For CAP, FDA requested additional clinical studies with microbiologic confirmation of bacterial infection. ...